Indications for: ZITHROMAX INJECTION
Susceptible infections including community-acquired pneumonia, pelvic inflammatory disease (PID).
Give by IV infusion 1mg/mL over 3hrs or 2mg/mL over 1hr. ≥16yrs: Pneumonia: 500mg once daily for at least 2 days, switch to 500mg orally once daily, for a total of 7–10 days combined therapy. PID: 500mg once daily for 1–2 days, switch to 250mg orally once daily for a total of 7 days combined therapy.
<16yrs: not established.
ZITHROMAX INJECTION Contraindications:
Ketolide allergy. History of cholestatic jaundice/hepatic dysfunction associated with prior use.
ZITHROMAX INJECTION Warnings/Precautions:
Pneumonia: oral treatment is for mild, community-acquired cases suitable for outpatient therapy only. Discontinue if signs/symptoms of hepatitis occur. Known QT prolongation, proarrhythmic conditions, clinically significant bradycardia: avoid. Potential risk of cardiovascular death. Allergic symptoms may recur after initial successful symptomatic treatment. Myasthenia gravis. Hepatic or renal impairment. Elderly. Pregnancy. Nursing mothers: monitor infants.
ZITHROMAX INJECTION Classification:
ZITHROMAX INJECTION Interactions:
Avoid concomitant aluminum- or magnesium-containing antacids. Monitor with digoxin, colchicine, phenytoin, warfarin. Monitor for azithromycin toxicity (eg, liver dysfunction, ototoxicity) with nelfinavir. Concomitant Class 1A (eg, quinidine, procainamide), or Class III (eg, dofetilide, amiodarone, sotalol) antiarrhythmics, or others known to prolong the QT interval: avoid.
Diarrhea, nausea, abdominal pain, vomiting, rash; hepatotoxicity, torsade de pointes (esp. elderly), C. difficile associated diarrhea; rare: allergic reactions (eg, angioedema, AGEP, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), lab abnormalities.
Generic Drug Availability:
Tabs—30; Z-Pak (6 x 250mg tabs)—3; Tri-Pak (3 x 500mg tabs)—3; Susp 100mg/5mL—15mL; 200mg/5mL—15mL, 22.5mL, 30mL; Single Dose Packets—3, 10; Inj—10